Heinecker R
MMW Munch Med Wochenschr. 1977 Jan 7;119(1):7-10.
The standard treatment of ischemic heart disease consists in the administration of nitrates and beta-sympathicolytic agents. Calcium antagonists are likewise promising. They should be used particularly if beta-sympathicolytic agents are contraindicated. In the beginning special caution should be exercised on combining a beta-sympathicolytic agent with a calcium antagonist. This is best done under clinical supervision since sudden cardiac decompensation, extreme bradycardia and/or disturbed atrioventricular conduction is to be expected. Today the administration of "coronary dilators" is no longer a part of the standard treatment but can at best be regarded as supplementary therapy.
缺血性心脏病的标准治疗包括使用硝酸盐类药物和β-交感神经阻滞剂。钙拮抗剂同样具有前景。特别是在β-交感神经阻滞剂禁忌时应使用钙拮抗剂。开始时,将β-交感神经阻滞剂与钙拮抗剂联合使用时应格外谨慎。最好在临床监测下进行,因为可能会出现心脏突然失代偿、极度心动过缓和/或房室传导障碍。如今,“冠状动脉扩张剂”的使用已不再是标准治疗的一部分,充其量只能视为辅助治疗。